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ABSTRACT
Introduction: Behçet´s syndrome is a systemic vasculitis characterized by recurrent oral and/or genital ulcers, and several systemic 
manifestations. The authors describe the case of a pediatric-onset Behçet´s syndrome. 
Case report: An 11-year-old boy was referred to the Pediatric consultation after two episodes of great saphenous vein thrombophlebitis. 
He had experienced daily oral aphthae for the past three years, and various episodes of folliculitis with pustule formation. Laboratory study 
was normal. The boy showed no signs of uveitis. The diagnosis of Behçet´s syndrome diagnosis was established according to the international 
criteria, with positive HLA- B51 testing. Colchicine was initiated, with favourable response. 
Conclusions: Due to clinical feature overlap with other conditions, Behçet’s syndrome diagnosis remains challenging. Consensus pediatric 
classification criteria developed in 2016 enabled greater sensitivity and earlier diagnosis. 
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RESUMO
Introdução: A síndrome de Behçet é uma vasculite caracterizada por episódios recorrentes de aftas orais e/ou genitais e manifestações 
sistémicas diversas. Os autores descrevem um caso de Síndrome de Behçet em idade pediátrica.
Caso clínico: Um adolescente de 11 anos foi referenciado à consulta de Pediatria após dois episódios de tromboflebite da veia safena magna. 
Reportou episódios recorrentes de lesões aftosas nos últimos três anos e vários episódios de foliculite com a formação de pústulas. O estudo 
analítico foi normal. O exame oftalmológico não demonstrou sinais de uveíte. Foi diagnosticada Síndrome de Behçet de acordo com critérios 
internacionais. O estudo genético foi positivo para o antigénio HLA-B51. Foi iniciada colchicina, com resposta favorável.
Conclusões: Devido à sobreposição de características clínicas com outras condições, o diagnóstico de Síndrome de Behçet permanece 
um desafio. Os critérios de classificação em idade pediátrica, elaborados em 2016, permitiram uma maior sensibilidade e diagnóstico mais 
precoce. 
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INTRODUCTION
Behçet´s syndrome (BS), also known as Behçet´s disease, is a systemic 
vasculitis involving blood vessels of any diameter. It is characterized 
by recurrent oral ulcers affecting the oral and genital mucosa and skin 
lesions. It also comprises several systemic manifestations, including 
ocular, neurological, cardiovascular or gastrointestinal involvement, 
and arthritis. Among systemic vasculitides, BS stands out for its ability 
to affect both venous and arterial blood vessels of all sizes.1,2
Although previously defined as a very rare entity, recent studies 
show that BS is more frequent than initially suspected. Its prevalence 
ranges from 5.2 to 7.1 cases per 100,000 adults in the USA and 
France, respectively.3,4 Overall prevalence is similar between men 
and women. The disease typically affects young adults aged 20 to 
40 years, but in 4−26% of cases it is also observed in children before 
the age of 16.5
Although BS has been classified as a vasculitis, its underlying cause 
remains unclear. Aberrant immune activity triggered by a specific 
agent in patients with genetic predisposition has been suggested 
Table 1 - International classification criteria for Behçet´s disease 1990 Table 2 - International classification criteria for Behçet´s disease 2014
as the underlying pathogenesis.6 A number of disease mechanisms, 
including genetic predisposition (e.g. association with certain human 
leukocyte antigens (HLA) and non-HLA genes), altered host bacteria 
response, altered hematopoietic stem cell populations and respective 
cytokines, presence of immune complexes and autoantibodies, and 
vascular endothelial activation and hypercoagulability have been 
suggested. Triggers may include viral or bacterial antigens or other 
environmental materials, such as chemicals or heavy metals.6
BS diagnosis is based on clinical features. The most used classification 
was proposed by the International Study Group for Behçet´s disease 
in 1990 and includes recurrent oral ulceration at least three times a 
year as mandatory feature, along with at least two additional minor 
criteria (Table 1).7 Low criteria sensitivity led to a revision in 2014, 
which added neurological and vascular features to criteria (Table 2).8 
Still, a validated, sensitive, and specific BS definition in pediatric age 
remains absent.9
The authors present a case of pediatric-onset Behçet´s syndrome 
with HLA-B51 positivity.
Criterion Definition
Recurrent oral 
ulceration
Aphthous (idiopathic) ulceration , 
observed by clinician or patient, with at 
least three episodes in a year
Plus at least two of 
the following:
Recurrent genital 
ulceration
Aphthous ulceration or scarring, 
observed by clinician or patient, at least 
once
Ocular lesions
Anterior or posterior uveitis seen in slit-
lamp examination; or retinal vasculitis 
documented by ophthalmologist
Cutaneous lesions
Erythema nodosum-like lesions observed 
by clinician or patient; papulopustular 
skin lesions or pseudofolliculitis, or 
characteristic acneiform nodules (post 
adolescent, not receiving steroids)
Positive pathergy test
Done by needle prick or intradermal 
saline injection and read at 48 hours 
by a physician (positive reactions 
include papula, pustule or papula with 
surrounding erythema)
Criterion Definition Value
Oral aphthosis 2
Genital 
ulceration
2
Ocular lesions
Anterior or posterior uveitis, retinal 
vasculitis
2
Cutaneous 
lesions
Pseudofolliculitis, skin aphthosis, 
erythema nodosum
1
Central 
nervous system 
involvement
1
Vascular 
manifestations
Arterial thrombosis, large vein 
thrombosis, phlebitis or superficial 
phlebitis
1
Positive 
pathergy test
Pathergy testing is optional and 
the primary scoring system does 
not include pathergy testing. When 
conducted, one extra point may be 
assigned for a positive result.
1
Note: Diagnosis is established if total score is ≥ 4
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CASE REPORT
An 11-year-old boy with a history of recurrent oral aphthae was 
admitted to the Emergency Department due to pain, redness, 
and warmth on the inner surface of the left leg with two weeks of 
evolution, without fever. On physical examination, painful swelling 
along a venous path on the left leg with inflammatory signs was 
identified. Dorsalis pedis pulse was bilaterally palpable. A lower limb 
echo-Doppler ultrasound confirmed thrombophlebitis of the great 
superficial saphenous vein. The boy was discharged with enoxaparin 
20 mg for two weeks and referred to outpatient consultation. After 
almost four months with no intercurrences, he was readmitted to 
the Emergency Department due to a second episode of swelling, 
redness, and warmth on the inner surface of the left leg. On physical 
examination, the patient showed local inflammatory signs without 
gait impairment and several oral aphthae. Case was discussed with 
a vascular surgeon and the patient was medicated with another 
course of enoxaparin 20 mg for two weeks and discharged with 
recommendation of rest, lower limb elevation, and oral hydration. 
In the first Pediatric outpatient consultation, the patient reported 
a history of daily painful oral aphthae (Figures 1 and 2) with 
spontaneous resolution after ten days for the past three years (more 
than three episodes a year). His mother described several episodes 
of lower limb folliculitis with pustule formation over the previous 
months. She also referred episodes of erythema and pain in the 
metatarsophalangeal joints of the right toe.
Figure 1 - Oral aphthae observed in the patient Figure 2 - Papulopustular lesion observed in the patient
The patient denied fever, rash, weight gain or loss, syncope, sleep 
disturbance, headache, abdominal pain, change in bowel habits or 
bladder function, respiratory symptoms, visual disturbances, or 
fatigue. Recent infections were not reported. Physical examination 
was normal, except for two oral aphthae and some acneiform 
lesions, prompting more accurate investigation of systemic lupus 
erythematosus and Behçet ´s syndrome.
Laboratory study included complete blood count with renal and 
hepatic function, C-reactive protein, coagulation study, hepatitis 
B and C and HIV viral markers, herpes simplex and varicella-zoster 
virus serology, and calprotectin levels, which were all negative. 
Immunoglobulin levels were normal and autoimmunity study 
including rheumatoid factor, antinuclear antibodies, anti-cardiolipin 
and beta 2 glycoprotein antibodies, lupus anticoagulant, anti-
extractable nuclear antigen (ENA), anti-neutrophil cytoplasmic 
(ANCA) antibodies, and celiac disease markers were negative. Urine 
analysis revealed discrete proteinuria and pathergy test was negative. 
On Dermatology consultation five months after the initial vascular 
event, no findings were documented except for some acneiform 
lesions. Echocardiogram was normal and ophthalmologic evaluation 
showed no signs of uveitis.
According to the International Criteria for Behçet´s disease 2014 
(Table 2), the patient scored four (recurrent oral aphthosis, cutaneous 
lesions, and vascular signs) and was diagnosed with Behçet´s 
syndrome. HLA- B51 test, which was later requested, was positive.
Approximately one year after the first vascular event, the patient 
reported a genital ulcer episode, adding another item to the 
international clinical diagnostic criteria.
After diagnosis, he was prescribed oral colchicine 1.5 mg per day, 
with subsequent reduction of oral aphthous lesion number and size. 
No further occurrences were reported, except for one self-limited 
epididymitis episode.
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DISCUSSION
Due to clinical feature overlap with several other conditions, 
especially autoinflammatory diseases, inflammatory bowel diseases, 
and immunodeficiencies, BS diagnosis remains challenging.9 As oral 
aphthous ulcers are common in the general population compared 
with BS, which has a relatively low incidence, diagnosis should be 
suspected in presence of recurrent aphthous ulcers along with 
characteristic systemic manifestations, particularly ocular lesions and 
neurological and vascular disease. No pathognomonic laboratory for 
the condition is in place and diagnosis is based on clinical findings. 
Consensus classification criteria have been recently developed for 
pediatric Behçet´s syndrome (Table 3), in an attempt to increase prior 
criteria sensitivity.9
Mucocutaneous lesions remain the main clue for BS diagnosis. 
Ocular lesions are the second most prominent lesion type, occurring 
in 25-75% of patients.1 Bilateral episodic uveitis is the dominant 
feature.10 As in the present case, approximately 20−40% of children 
report articular involvement, generally arthralgia, mostly in the 
knees, ankles, elbows, and wrists. Neurological manifestations 
include acute features, such as recurrent aseptic meningitis and 
meningoencephalitis, and chronic features, such as progressive 
parenchymal and vascular lesions. The latter usually manifest 
as cognitive impairment, memory loss, depression, anxiety, 
pseudobulbar syndrome, and sensitive and motor deficits. The 
most common presentations in pediatric age are cerebral venous 
thrombosis and cranial nerve palsy, especially of the VIth nerve.1
Most BS clinical manifestations are attributed to vasculitis, which can 
affect both arterial and venous blood vessels of all sizes. Prevalence 
of pediatric vascular disease was reported to range from 9.6% to 15% 
in two case series and have a high relapse rate, as observed in this 
case.5,11
Although ileum and colon are the most commonly affected 
intestinal sites, all gastrointestinal tract can be affected. Isolated 
abdominal pain, diarrhea, and bleeding are among the most 
prevalent symptoms.1
In BS, renal involvement is less severe and less frequent compared 
with other vasculitides. Patients may present proteinuria, as in the 
present case, hematuria, or mild renal insufficiency. The first two 
may occur in up to 10% of patients.12
Cardiac manifestations include pericarditis, myocarditis, and 
intracardiac thrombus. Orchitis, epididymitis, urethritis, and sterile 
cystitis cases, although rare, have been described.1
A study conducted by Koné-Paut et al. in 1999 reported a 
significantly higher frequency of familial cases in pediatric compared 
with non-pediatric BS patients, suggesting a strong genetic 
component.13 Presence of the HLA-B51 antigen, as in this case report, 
has been associated with an increased risk of BS and disease severity. 
Nevertheless, absence of HLA-B51 antigen does not exclude BS.1
BS has a recurrent and unpredictable course, often remaining active 
in children with new symptom onset over time. Morbidity is usually 
related to neurological and ocular disease.1 Mortality, on the other 
hand, is associated with vascular disease, malignancy, central nervous 
system involvement, and sepsis. Younger age, male gender, high 
flare number, and arterial involvement are risk factors for death.14 
Consequently, these patients require periodic ophthalmological 
evaluation and close monitoring of prothrombotic states. 
No specific treatment is established for BS. Treatment goal is 
suppression of inflammatory exacerbations and recurrences to 
prevent irreversible organ damage. Following the 2018 update of the 
European League Against Rheumatism (EULAR) recommendations 
for BS management, the present patient was prescribed colchicine 
for preventing recurrent mucocutaneous lesions, with clinical 
improvement. Use of topical steroids is recommended for oral 
and genital ulcer treatment, as well as for papulopustular or acne-
like lesions. Glucocorticoids and immunosuppressive therapy, 
such as azathioprine, cyclophosphamide, or cyclosporine A, are 
recommended for acute deep vein thrombosis management.15 Since 
this patient only had superficial venous thrombotic events, none of 
these agents was employed. 
Criterion Definition Value
Recurrent oral aphthosis At least three attacks/year 1
Genital ulceration or aphtosis Typically with scar 1
Skin involvement
Necrotic folliculitis, acneiform lesions, 
erythema nodosum
1
Ocular involvement
Anterior uveitis, posterior uveitis, retinal 
vasculitis
1
Neurological signs With the exception of isolated headaches 1
Vascular signs
Venous thrombosis, arterial thrombosis, 
arterial aneurysm
1
Table 3 - Consensus classification of pediatric Behçet´s disease 2016
Three of six items are required to diagnose a patient with pediatric Behçet´s disease
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